On September 4, Takeda China announced that the updated version of its recombinant human coagulation factor VIII (FVIII) dosing software, myPKFiT®, received approval from the National Medical Products Administration (NMPA). The new version includes optimizations for the healthcare professional application and, for the first time, adds personalized features.HemophiliaA mobile application for patients, facilitating the maintenance and execution of individualized dosing regimens, providing support for their return to normal life.myPKFiT® is an individualized prophylactic Factor VIII dosing calculation software, which is used in conjunction with Takeda's recombinant human Factor VIII for injection (brand name: ADVATE, launched in China in 2013).
Source| People's Daily Health Client
Rare Neurological Disorders Communication Group
↓Click below "Read the original text", DownloadMedSci Medical APP!
